855 ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA AND LIVERG.A.E. van t Klooster,I. Vanwelkenhuysen,R. Hooijmaijers,K. Bol, M. Voets,J. Van Houdt,R.A.L. Verloes,F. Aharchi,K. Marien,P. Van Remoortere,F. Broeckaert,H. De Kock,K.A. SimmenJOURNAL OF HEPATOLOGY(2008)引用 7|浏览3暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要